1398P The impact of personalized prehabilitation on tolerance to chemotherapy in patients with gastric and oesophageal cancer. A controlled study

Abstract

Background: Prehabilitation programmes aim to optimise patients preoperatively to enhance post-operative recovery and outcome. Previous studies have demonstrated that prehabilitation can improve pre-operative fitness and can overcome the negative impact of neoadjuvant chemotherapy and chemoradiotherapy on fitness. The aim of this study was to assess the impact of prehabilitation on the tolerance of neoadjuvant chemotherapy in patients with gastric and oesophageal cancer.Methods: Patients with gastric or oesophageal cancer from two centres were compared; one provided a multimodal prehabilitation programme and one did not offer prehabilitation. The parameters evaluated for comparison between the two groups included age, Karnofsky and ASA scores, tumor location and histology, cycles of chemotherapy and radiotehrapy that were completed.Results: 135 patients were included in this study; 81 patients from the prehabilitation cohort and 54 in the control cohort. Compared with the control group, the prehabilitation group demonstrated improved rate of chemotherapy completion (p¼0.002). According to the multivariate analysis, the prehabilitation and radiotherapy were associated with improved tolerance of chemotherapy.Conclusions: Prehabilitation has previously been shown to negate the negative impact of neoadjuvant chemotherapy on pre-operative fitness. In parallel to this, this study has shown that prehabilitation is also associated with better tolerance of chemotherapy. Further research is needed to establish the long-term impact of prehabilitation on oncological outcomes.